Subgroup analysis: Refining a positive result or trying to rescue a negative one?

Journal of Clinical Oncology

Volumn 33, Issue 36, 2015, Pages 4310-

  Di Maio, Massimo ^a   Perrone, Francesco ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYSIS; EUROPEAN MEDICINES AGENCY; HUMAN; LETTER; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; SUBGROUP ANALYSIS; NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84957567749     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.6747     Document Type: Letter

References (2)

1. Zhang S, Liang F, Li W, et al: Subgroup analyses in reporting of phase III clinical trials in solid tumors. J Clin Oncol 33:1697-1702, 2015
2. European Medicines Agency: Guideline on the investigation of subgroups in confirmatory clinical trials. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500160523.pdf